A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy

Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlesi, Martin Kohlhäufl, Oscar Arrieta, Marco Angelo Burgio, Jérôme Fayette, Hervé Lena, Elena Poddubskaya, David E Gerber, Scott N Gettinger, Charles M Rudin, Naiyer Rizvi, Lucio Crinò, George R Blumenschein Jr, Scott J Antonia, Cécile Dorange, Christopher T Harbison, Friedrich Graf Finckenstein, Julie R Brahmer, None, Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 373, pp. 1627- 1639 ,(2015) , 10.1056/NEJMOA1507643

Asim Amin, Jeryl Villadolid, Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities Translational lung cancer research. ,vol. 4, pp. 560- 575 ,(2015) , 10.3978/J.ISSN.2218-6751.2015.06.06

Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried EE Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina C Garassino, Joachim G Aerts, Manuel Domine, Luis Paz-Ares, Martin Reck, Christine Baudelet, Christopher T Harbison, Brian Lestini, David R Spigel, None, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer The New England Journal of Medicine. ,vol. 373, pp. 123- 135 ,(2015) , 10.1056/NEJMOA1504627

Paul K. Paik, Alexander Drilon, Pang-Dian Fan, Helena Yu, Natasha Rekhtman, Michelle S. Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F. Berger, Charles M. Rudin, Marc Ladanyi, Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping Cancer Discovery. ,vol. 5, pp. 842- 849 ,(2015) , 10.1158/2159-8290.CD-14-1467

M.-J. Ahn, J. Yang, H. Yu, H. Saka, S. Ramalingam, K. Goto, S.-W. Kim, L. Yang, A. Walding, G.R. Oxnard, 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial Journal of Thoracic Oncology. ,vol. 11, ,(2016) , 10.1016/S1556-0864(16)30246-5

D.L. Gibbons, L.Q. Chow, D.-W. Kim, S.-W. Kim, T. Yeh, X. Song, H. Jiang, R. Taylor, J. Karakunnel, B. Creelan, 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC Journal of Thoracic Oncology. ,vol. 11, pp. S79- ,(2016) , 10.1016/S1556-0864(16)30171-X

Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist, Xiujun Fu, Christopher G. Azzoli, Zofia Piotrowska, Tiffany G. Huynh, Ling Zhao, Linnea Fulton, Katherine R. Schultz, Emily Howe, Anna F. Farago, Ryan J. Sullivan, James R. Stone, Subba Digumarthy, Teresa Moran, Aaron N. Hata, Yukako Yagi, Beow Y. Yeap, Jeffrey A. Engelman, Mari Mino-Kenudson, EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis Clinical Cancer Research. ,vol. 22, pp. 4585- 4593 ,(2016) , 10.1158/1078-0432.CCR-15-3101

Naiyer A. Rizvi, Matthew D. Hellmann, Julie R. Brahmer, Rosalyn A. Juergens, Hossein Borghaei, Scott Gettinger, Laura Q. Chow, David E. Gerber, Scott A. Laurie, Jonathan W. Goldman, Frances A. Shepherd, Allen C. Chen, Yun Shen, Faith E. Nathan, Christopher T. Harbison, Scott Antonia, Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 34, pp. 2969- 2979 ,(2016) , 10.1200/JCO.2016.66.9861

A. Dowlati, M.A. Huseni, S. Gettinger, V.M. Villaflor, B. Besse, D. Costa, A. Cervantes, R. Heist, C. O’Hear, B.B.Y. Ma, P. Foster, P. Schmid, I. Sarkar, C.M. Rudin, 441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC Annals of Oncology. ,vol. 27, ,(2016) , 10.1016/S0923-7534(21)00599-8

Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noe, Peter N Morcos, Tony Mok, None, Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 377, pp. 829- 838 ,(2017) , 10.1056/NEJMOA1704795